Cargando…

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature

Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martora, Fabrizio, Scalvenzi, Massimiliano, Ruggiero, Angelo, Potestio, Luca, Battista, Teresa, Megna, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146646/ https://www.ncbi.nlm.nih.gov/pubmed/37109759 http://dx.doi.org/10.3390/medicina59040801

Ejemplares similares

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
por: Battista, Teresa, et al.
Publicado: (2023)

Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?
por: Martora, Fabrizio, et al.
Publicado: (2023)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Teledermatology in the management of hidradenitis suppurativa: Should we improve this service?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
por: Potestio, Luca, et al.
Publicado: (2023)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
por: Potestio, Luca, et al.
Publicado: (2023)

How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis
por: Martora, Fabrizio, et al.
Publicado: (2023)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Secukinumab and hidradenitis suppurativa: Friends or foes?
por: Marasca, Claudio, et al.
Publicado: (2019)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
por: Martora, Fabrizio, et al.
Publicado: (2022)

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment
por: Napolitano, Maddalena, et al.
Publicado: (2017)

A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa
por: Marasca, Claudio, et al.
Publicado: (2018)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
por: Camela, Elisa, et al.
Publicado: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Comorbidities of hidradenitis suppurativa: A review of the literature
por: Cartron, Alexander, et al.
Publicado: (2019)

COVID‐19 and cutaneous manifestations: A review of the published literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

A case of linear psoriasis in a young patient with Down syndrome and review of the literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
por: Caiazzo, Giuseppina, et al.
Publicado: (2023)

TNF-α inhibitors in the treatment of hidradenitis suppurativa
por: Savage, Kevin T., et al.
Publicado: (2019)

Hidradenitis suppurativa in AIDS
por: Khambhati, Ravi, et al.
Publicado: (2010)

Hidradenitis suppurativa and intimacy
por: Jemec, G.
Publicado: (2018)

Ectopic Hidradenitis Suppurativa: Case Report and Review of Literature
por: Gutierrez, Nikolas, et al.
Publicado: (2021)

Coexistence of Hidradenitis Suppurativa and Steatocystoma Multiplex: Is It a New Variant of Hidradenitis Suppurativa?
por: Fletcher, Joshua, et al.
Publicado: (2021)

Management of Advanced Invasive Melanoma: New Strategies
por: Villani, Alessia, et al.
Publicado: (2023)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aqtds633246l1ppv02qipesaf6